Prime Healthcare

primehealthcare.com

Founded in 2001, Prime Healthcare has emerged as one of the nation’s leading hospital systems. Prime Healthcare was founded by Dr. Prem Reddy, a physician with a mission to save hospitals, improve community healthcare and provide the very best care to patients.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MedTech

ARBOR BIOTECHNOLOGIES ENTERS INTO AGREEMENT WITH ACUITAS THERAPEUTICS FOR LIPID NANOPARTICLE DELIVERY SYSTEM FOR USE IN RARE LIVER DISEASES

Arbor Biotechnologies Inc | August 29, 2022

news image

Arbor Biotechnologies, a biotechnology company discovering and developing the next generation of genetic medicines, today announced that it has entered into an agreement with Acuitas Therapeutics, a leader in the development of lipid nanoparticles. As part of the agreement, the companies will combine the optimized delivery of Acuitas' highly validated LNP technology with Arbor’s differentiated, proprietary CRISPR gene editing technology designed for use in vivo in patien...

Read More

Cell and Gene Therapy

NEW RESEARCH FROM THE CARIS PRECISION ONCOLOGY ALLIANCE FINDS PROGNOSTIC AND PREDICTIVE DRUG-INDUCED GENE SIGNATURES FOR COLORECTAL CANCER PATIENTS

Caris Life Sciences | April 11, 2022

news image

Caris Life Sciences®(Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, to present findings that provide a deeper understanding that tumor expression of genes related to extent of drug exposure, stratified by p53 status, is associated with clinical outcomes on the common chemotherapeutic regimens used to treat metastatic colorectal cancer (CRC). These results will be presented at the 2022 American ...

Read More

Cell and Gene Therapy

CASMA THERAPEUTICS RAISES $46.0 M IN SERIES C FUNDING

Casma Therapeutics, Inc. | November 21, 2022

news image

Casma Therapeutics, Inc., a biotechnology company engaging the autophagy system to provide innovative new medicines, announced the closing of a Series C financing round of $46.0 million. New investors participating in the round include Amgen Ventures, LLC, Astellas Venture Management, Eisai Co., Ltd., Euclidean Capital, Mirae Asset, and Ono Venture Investment. Current investors Eventide Asset Management, LLC, Schroders Capital, The Column Group, Third Rock Ventures, and other funds also particip...

Read More

Medical

CELLCARTA EXPANDS IT PROTEOMICS PORTFOLIO WITH THE ACQUISITION OF NEXT-GENERATION IMMUNO-MRM ASSAYS FROM PRECISION ASSAYS

CellCarta | May 23, 2022

news image

CellCarta, a leading global provider of precision medicine laboratory services, announced today the acquisition of the commercial rights to the antibody panels and assays from Precision Assays, a leader in next-generation targeted proteomics testing solutions. A spin-off from Fred Hutchinson Cancer Center ("Fred Hutch"), Precision Assays develops and deploys high-end multiplex quantitative immuno-MRM mass spectrophotometry-based assays for its pharmaceutical and biotech industry client...

Read More
news image

MedTech

ARBOR BIOTECHNOLOGIES ENTERS INTO AGREEMENT WITH ACUITAS THERAPEUTICS FOR LIPID NANOPARTICLE DELIVERY SYSTEM FOR USE IN RARE LIVER DISEASES

Arbor Biotechnologies Inc | August 29, 2022

Arbor Biotechnologies, a biotechnology company discovering and developing the next generation of genetic medicines, today announced that it has entered into an agreement with Acuitas Therapeutics, a leader in the development of lipid nanoparticles. As part of the agreement, the companies will combine the optimized delivery of Acuitas' highly validated LNP technology with Arbor’s differentiated, proprietary CRISPR gene editing technology designed for use in vivo in patien...

Read More
news image

Cell and Gene Therapy

NEW RESEARCH FROM THE CARIS PRECISION ONCOLOGY ALLIANCE FINDS PROGNOSTIC AND PREDICTIVE DRUG-INDUCED GENE SIGNATURES FOR COLORECTAL CANCER PATIENTS

Caris Life Sciences | April 11, 2022

Caris Life Sciences®(Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, to present findings that provide a deeper understanding that tumor expression of genes related to extent of drug exposure, stratified by p53 status, is associated with clinical outcomes on the common chemotherapeutic regimens used to treat metastatic colorectal cancer (CRC). These results will be presented at the 2022 American ...

Read More
news image

Cell and Gene Therapy

CASMA THERAPEUTICS RAISES $46.0 M IN SERIES C FUNDING

Casma Therapeutics, Inc. | November 21, 2022

Casma Therapeutics, Inc., a biotechnology company engaging the autophagy system to provide innovative new medicines, announced the closing of a Series C financing round of $46.0 million. New investors participating in the round include Amgen Ventures, LLC, Astellas Venture Management, Eisai Co., Ltd., Euclidean Capital, Mirae Asset, and Ono Venture Investment. Current investors Eventide Asset Management, LLC, Schroders Capital, The Column Group, Third Rock Ventures, and other funds also particip...

Read More
news image

Medical

CELLCARTA EXPANDS IT PROTEOMICS PORTFOLIO WITH THE ACQUISITION OF NEXT-GENERATION IMMUNO-MRM ASSAYS FROM PRECISION ASSAYS

CellCarta | May 23, 2022

CellCarta, a leading global provider of precision medicine laboratory services, announced today the acquisition of the commercial rights to the antibody panels and assays from Precision Assays, a leader in next-generation targeted proteomics testing solutions. A spin-off from Fred Hutchinson Cancer Center ("Fred Hutch"), Precision Assays develops and deploys high-end multiplex quantitative immuno-MRM mass spectrophotometry-based assays for its pharmaceutical and biotech industry client...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us